LMAO

Aware Unveils The Real Reasons Why Retail Employees Quit

Retrieved on: 
Thursday, August 17, 2023

COLUMBUS, Ohio, Aug. 17, 2023 /PRNewswire/ -- Aware, the AI Data Platform powering Experience Management, today released its latest research on workplace trends directly from the voices of retail employees. Utilizing its state-of-the-art AI-powered platform, which recently outperformed Meta's Llama-2 in a direct competition, Aware ingested, normalized, enriched, and analyzed over 150,000 anonymized workplace conversations across eight major retail brands on social media platforms such as Reddit and other sources. 

Key Points: 
  • COLUMBUS, Ohio, Aug. 17, 2023 /PRNewswire/ -- Aware, the AI Data Platform powering Experience Management, today released its latest research on workplace trends directly from the voices of retail employees.
  • This intelligence sheds light into the contributing factors to the alarming 60% retail turnover rate, which McKinsey Consulting calls the "Great Attrition".
  • Aware's purpose-built Natural Language Processing (NLP) models painted a vivid picture of employees caught in the crossfire of a cultural clash with customers.
  • For a comprehensive look at Aware's Retail Workplace Trends Report and to delve into these insights, click here .

SeaStar Medical Reports 2022 Financial Results and Provides a Business Update

Retrieved on: 
Friday, March 31, 2023

DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022.

Key Points: 
  • DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022.
  • “We are focusing on executing near-term milestones that will advance our business,” said Eric Schlorff, SeaStar Medical CEO.
  • The NEUTRALIZE-AKI trial is expected to enroll up to 200 patients at up to 30 U.S. medical centers.
  • In March 2023 SeaStar Medical closed a $3.3 million first tranche of a $9.8 million private placement convertible debt offering.

SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development

Retrieved on: 
Friday, December 2, 2022

DENVER, COLORADO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (SeaStar Medical or the Company), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Thomas R. Mullen as Vice President of Operations and Product Development.

Key Points: 
  • DENVER, COLORADO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (SeaStar Medical or the Company), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Thomas R. Mullen as Vice President of Operations and Product Development.
  • Mr. Mullen is a proven medical device professional with 30 years of experience leading business operations, manufacturing, engineering, product development and regulatory remediation.
  • SeaStar Medical has continued to evolve and remains on a trajectory of growth including near-term potential for commercialization.
  • Since 1993, Mr. Mullen has led Mullen Business Development, a manufacturing, engineering and operations consulting firm.

SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors

Retrieved on: 
Tuesday, November 29, 2022

DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (SeaStar Medical or the Company), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Rick Barnett as Chairman of the Companys Board of Directors.

Key Points: 
  • DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (SeaStar Medical or the Company), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Rick Barnett as Chairman of the Companys Board of Directors.
  • Mr. Barnett has served on the SeaStar Medical Board as a Director since January 2021, and currently serves as Chair of the Compensation Committee and a member of the Audit Committee.
  • Mr. Barnett joined SeaStar Medicals Board of Directors after serving as President, Chief Executive Officer and Board Member of Satellite Healthcare, Inc. for seven years.
  • Mr. Barnett is the Chairman of the board of directors of the National Kidney Foundation California, Nevada & Pacific Northwest Region.

SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting

Retrieved on: 
Monday, November 7, 2022

DENVER, COLORADO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced its Selective Cytopheretic Device (SCD) has been included in the Consensus Statement for pediatric acute kidney injury (AKI) as part of the first Pediatric Acute Disease Quality Initiative (pADQI) meeting. The outcome of the meeting, titled “Consensus-Based Recommendations on Priority Activities to Address Acute Kidney Injury in Children,” has been published in JAMA Network Open1.

Key Points: 
  • The outcome of the meeting, titled Consensus-Based Recommendations on Priority Activities to Address Acute Kidney Injury in Children , has been published in JAMA Network Open1.
  • The first pediatric ADQI convened in November 2021 to develop expert-driven pediatric specific recommendations on AKI.
  • Its primary aim was to identify the work priorities across the pediatric AKI landscape of care, education, research and advocacy.
  • We are extremely pleased to have SeaStar Medicals SCD included in the Consensus Statement of ADQI, which builds upon the existing support within the pediatric community for this important therapy.

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Retrieved on: 
Thursday, November 3, 2022

DENVER, COLORADO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced positive interim data in a poster presentation at the American Society of Nephrology (ASN) Kidney Week 2022 taking place November 3-6, 2022 in Orlando, FL.

Key Points: 
  • The study is evaluating children that weigh between 10 and 20kg, have a clinical diagnosis of AKI requiring CKRT and at least one non-renal organ failure.
  • With these subjects the SCD was integrated post CKRT membrane, changed daily, and circuit ionized calcium (iCa) maintained
  • Subjects received SCD treatment for up to 10 days or CKRT discontinuation, whichever came first.
  • Dr. Goldstein served as a consultant to SeaStar Medical in the preparation and submission of the HDE application.

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts

Retrieved on: 
Monday, October 31, 2022

Denver, Colorado, Oct. 31, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the commencement of trading on the Nasdaq Capital Market under the ticker symbol “ICU” having successfully completed its previously announced definitive agreement for a business combination transaction with LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company. The Company also provided a business outlook and outlined key upcoming milestones.

Key Points: 
  • SeaStar Medical has continued to deliver on its promises with operational excellence.
  • In addition to the progress weve made on the corporate front, we continue to advance our innovative SCD therapy platform.
  • I am excited for what is to come and look forward to providing updates as we execute on the milestones ahead.
  • Denver-based SeaStar Medical (Nasdaq: ICU) is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs.

SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities

Retrieved on: 
Friday, October 28, 2022

DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA). The business combination closed on October 28, 2022.

Key Points: 
  • DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA).
  • Following the closing of the business combination, LMF Acquisition Opportunities, Inc. was renamed SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, which is led by Eric Schlorff, CEO.
  • Maxim Group LLC served as sole financial advisor and Morgan Lewis & Bockius LLP served as legal counsel to SeaStar Medical in connection with the business combination.
  • These forward-looking statements include, without limitation, SeaStar Medical Holding Corporations, LMAOs and SeaStar Medicals expectations with respect to the proposed business combination between LMAO and SeaStar Medical, including statements regarding the benefits of the transaction, the ability of SeaStar Medical Holding Corporation to achieve value for its stakeholders, the implied valuation of SeaStar Medical, the products offered by SeaStar Medical Holding Corporation and the markets in which it operates, and the expected timing of regulatory approval of SeaStar Medical Holding Corporations products.

LMF Acquisition Opportunities, Inc. Stockholders Approve Previously Announced Business Combination with SeaStar Medical, Inc.

Retrieved on: 
Tuesday, October 18, 2022

More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical.

Key Points: 
  • More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical.
  • Denver-based SeaStar Medical, Inc. is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs.
  • SeaStar Medicals novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients.
  • LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination

Retrieved on: 
Wednesday, September 28, 2022

DENVER and TAMPA, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA), and SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that LMAO’s registration statement on Form S-4 (“Registration Statement”) related to the two companies’ previously announced business combination was declared effective by the U.S. Securities and Exchange Commission on September 26, 2022.

Key Points: 
  • LMAO commenced mailing to stockholders on September 28, 2022 the definitive proxy statement relating to the special meeting of LMAO stockholders (the Special Meeting).
  • The Special Meeting to approve the pending business combination and other related matters is scheduled for October 18, 2022 at 10:00 a.m. Eastern Time.
  • The Special Meeting will be held at LMAOs office located at 1200 W. Platt St., Suite 100, Tampa, Florida 33606.
  • LMAOs board of directors unanimously recommends that its stockholders vote FOR each of the proposals, including the proposed business combination.